Cathepsin S cleavage of protease-activated receptor-2 on endothelial cells promotes microvascular diabetes complications

Journal of the American Society of Nephrology

Volumn 27, Issue 6, 2016, Pages 1635-1649

  Santhosh Kumar, V R ^a   Darisipudi, Murthy N ^a   Steiger, Stefanie ^a   Devarapu, Satish Kumar ^a   Tato, Maia ^a   Kukarni, Onkar P ^a   Mulay, Shrikant R ^a   Thomasova, Dana ^a   Popper, Bastian ^b   Demleitner, Jana ^c   Zuchtriegel, Gabriele ^a,d   Reichel, Christoph ^a,d   Cohen, Clemens D ^e,f   Lindenmeyer, Maja T ^a   Liapis, Helen ^g   Moll, Solange ^h   Reid, Emma ⁱ   Stitt, Alan W ⁱ   Schott, Brigitte ^j   Gruner, Sabine ^j   Haap, Wolfgang ^j   Ebeling, Martin ^j   Hartmann, Guido ^j   Anders, Hans Joachim ^a   more..

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

^c Walther Straub Institut for Pharmakologie und Toxikologie   (Germany)

^d Walter Brendel Centre of Experimental Medicine   (Germany)

^e Krankenhaus Harlaching   (Germany)

^f UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^g WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h GENEVA UNIVERSITY HOSPITALS   (Switzerland)

ⁱ QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^j F HOFFMANN LA ROCHE LTD   (Switzerland)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CATHEPSIN S; CD68 ANTIGEN; CYSTATIN C; PROTEINASE ACTIVATED RECEPTOR 2; SMALL INTERFERING RNA; TRANSCRIPTOME; CATHEPSIN; PROLINE; RO5461111;

ALBUMINURIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL PERMEABILITY; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC NEPHROPATHY; ENDOTHELIUM CELL; GLOMERULOSCLEROSIS; HUMAN; HUMAN TISSUE; IN VITRO STUDY; INTRAVITAL MICROSCOPY; KIDNEY BIOPSY; KIDNEY PROXIMAL TUBULE; KIDNEY TUBULE CELL; MALE; MICROANGIOPATHY; MONOCYTE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN CLEAVAGE; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL CULTURE; CYTOLOGY; DIABETIC ANGIOPATHIES; ENZYMOLOGY; GLOMERULUS; METABOLISM; MICROVASCULATURE; PHYSIOLOGY; UROTHELIUM;

ANIMALS; CATHEPSINS; CELLS, CULTURED; DIABETIC ANGIOPATHIES; ENDOTHELIAL CELLS; KIDNEY GLOMERULUS; MALE; MICE; MICROVESSELS; PROLINE; RECEPTOR, PAR-2; UROTHELIUM;

EID: 85014079951     PISSN: 10466673     EISSN: 15333450     Source Type: Journal    
DOI: 10.1681/ASN.2015020208     Document Type: Article

References (51)

1. Advani A, Gilbert RE: The endothelium in diabetic nephropathy. Semin Nephrol 32: 199-207, 2012
2. Nakagawa T, Tanabe K, Croker BP, Johnson RJ,GrantMB, Kosugi T, LiQ: Endothelial dysfunction as a potential contributor in diabetic nephropathy. Nat Rev Nephrol 7: 36-44, 2011
3. Ritz E: Albuminuria and vascular damage-The vicious twins. N Engl J Med 348: 2349-2352, 2003
4. FoxCS,Matsushita K,WoodwardM, BiloHJ, Chalmers J, Heerspink HJ, Lee BJ, Perkins RM, Rossing P, Sairenchi T, Tonelli M, Vassalotti JA, Yamagishi K, Coresh J, de Jong PE, Wen CP, Nelson RG; Chronic Kidney Disease Prognosis Consortium: Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: A meta-analysis. Lancet 380: 1662-1673, 2012
5. Qian Y, Feldman E, Pennathur S, Kretzler M, Brosius FC 3rd: From fibrosis to sclerosis: Mechanisms of glomerulosclerosis in diabetic nephropathy. Diabetes 57: 1439-1445, 2008
6. Ruggenenti P, Perticucci E, Cravedi P, Gambara V, Costantini M, Sharma SK, Perna A, Remuzzi G: Role of remission clinics in the longitudinal treatment of CKD. J Am Soc Nephrol 19: 1213-1224, 2008
7. Aikawa E, Aikawa M, Libby P, Figueiredo JL, Rusanescu G, Iwamoto Y, FukudaD, Kohler RH, Shi GP, Jaffer FA,Weissleder R: Arterial and aortic valve calcification abolished by elastolytic cathepsin S deficiency in chronic renal disease. Circulation 119: 1785-1794, 2009
8. Liu J, Sukhova GK, Sun JS, XuWH, Libby P, Shi GP: Lysosomal cysteine proteases in atherosclerosis. Arterioscler Thromb Vasc Biol 24: 1359-1366, 2004
9. Lutgens SP, Cleutjens KB, Daemen MJ, Heeneman S: Cathepsin cysteine proteases in cardiovascular disease. FASEB J 21: 3029-3041, 2007
10. Jobs E, Ingelsson E, Riserus U, Nerpin E, Jobs M, Sundstrom J, Basu S, Larsson A, Lind L, Arnlov J: Association between serumcathepsin S and mortality in older adults. JAMA 306: 1113-1121, 2011
11. Jobs E, Riserus U, Ingelsson E, Sundstrom J, JobsM, Nerpin E, Iggman D, Basu S, Larsson A, Lind L, Arnlov J: Serum cathepsin S is associated with decreased insulin sensitivity and the development of type 2 diabetes in a community-based cohort of elderlymen. Diabetes Care 36: 163-165, 2013
12. Cheng XW, Huang Z, Kuzuya M, Okumura K, Murohara T: Cysteine protease cathepsins in atherosclerosis-based vascular disease and its complications. Hypertension 58: 978-986, 2011
13. Cox JM, Troutt JS, KniermanMD, Siegel RW, Qian YW, Ackermann BL, Konrad RJ: Determination of cathepsin S abundance and activity in human plasma and implications for clinical investigation. Anal Biochem 430: 130-137, 2012
14. Lafarge JC,NaourN, Clement K,Guerre-MilloM:Cathepsins and cystatin C in atherosclerosis and obesity. Biochimie 92: 1580-1586, 2010
15. Smith ER, Tomlinson LA, Ford ML, McMahon LP, Rajkumar C, Holt SG: Elastin degradation is associated with progressive aortic stiffening and all-cause mortality in predialysis chronic kidney disease. Hypertension 59: 973-978, 2012
16. Elmariah SB, Reddy VB, Lerner EA: Cathepsin S signals via PAR2 and generates a novel tethered ligand receptor agonist. PLoS One 9: e99702, 2014
17. Rupanagudi KV, Kulkarni OP, Lichtnekert J, Darisipudi MN, Mulay SR, Schott B, Gruner S, Haap W, Hartmann G, Anders HJ: Cathepsin S inhibition suppresses systemic lupus erythematosus and lupus nephritis because cathepsin S is essential for MHC class II-mediated CD4 T cell and B cell priming. Ann Rheum Dis 74: 452-463, 2015
18. Xiao C, Lachance B, Sunahara G, Luong JHT: An in-depth analysis of electric cell-substrate impedance sensing to study the attachment and spreading mammalian cells. Anal Chem 74: 1333-1339, 2002
19. Liu J,MaL, Yang J, Ren A, Sun Z, YanG, Sun J, FuH, XuW,Hu C, ShiGP: Increased serum cathepsin S in patients with atherosclerosis and diabetes. Atherosclerosis 186: 411-419, 2006
20. Roy MS, Janal MN, Crosby J, Donnelly R: Markers of endothelial dysfunction and inflammation predict progression of diabetic nephropathy in African Americans with type 1 diabetes. Kidney Int 87: 427-433, 2015
21. Dinneen SF, Gerstein HC: The association of microalbuminuria and mortality in non-insulin-dependent diabetes mellitus. A systematic overview of the literature. Arch Intern Med 157: 1413-1418, 1997
22. Ruggenenti P, Porrini E, Motterlini N, Perna A, Ilieva AP, Iliev IP, Dodesini AR, Trevisan R, Bossi A, Sampietro G, Capitoni E, Gaspari F, Rubis N, Ene-Iordache B, Remuzzi G; BENEDICT Study Investigators: Measurable urinary albumin predicts cardiovascular risk among normoalbuminuric patients with type 2 diabetes. J Am Soc Nephrol 23: 1717-1724, 2012
23. Ninomiya T, Perkovic V, de Galan BE, Zoungas S, Pillai A, Jardine M, Patel A, Cass A, Neal B, Poulter N, Mogensen CE, Cooper M, MarreM, Williams B, Hamet P,Mancia G,WoodwardM,Macmahon S, Chalmers J; ADVANCE Collaborative Group: Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes. J Am Soc Nephrol 20: 1813-1821, 2009
24. Hillege HL, Fidler V, Diercks GF, van Gilst WH, de Zeeuw D, van Veldhuisen DJ, Gans RO, Janssen WM, Grobbee DE, de Jong PE; Prevention of Renal and Vascular End Stage Disease (PREVEND) Study Group: Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation 106: 1777-1782, 2002
25. Shi GP, Sukhova GK, Grubb A, Ducharme A, Rhode LH, Lee RT, Ridker PM, Libby P, Chapman HA: Cystatin C deficiency in human atherosclerosis and aortic aneurysms. J Clin Invest 104: 1191-1197, 1999
26. Pober JS, Min W, Bradley JR: Mechanisms of endothelial dysfunction, injury, and death. Annu Rev Pathol 4: 71-95, 2009
27. Cheng H, Wang H, Fan X, Paueksakon P, Harris RC: Improvement of endothelial nitric oxide synthase activity retards the progression of diabetic nephropathy in db/db mice. Kidney Int 82: 1176-1183, 2012
28. Shi GP, Sukhova GK, Kuzuya M, Ye Q, Du J, Zhang Y, Pan JH, Lu ML, Cheng XW, Iguchi A, Perrey S, Lee AM, Chapman HA, Libby P: Deficiency of the cysteine protease cathepsin S impairs microvessel growth. Circ Res 92: 493-500, 2003
29. Galkina E, Ley K: Leukocyte recruitment and vascular injury in diabetic nephropathy. J Am Soc Nephrol 17: 368-377, 2006
30. Tuttle KR: Linking metabolism and immunology: Diabetic nephropathy is an inflammatory disease. J Am Soc Nephrol 16: 1537-1538, 2005
31. de Nooijer R, Bot I, von der Thusen JH, Leeuwenburgh MA, Overkleeft HS, Kraaijeveld AO, Dorland R, van Santbrink PJ, van Heiningen SH, Westra MM, Kovanen PT, Jukema JW, van der Wall EE, van Berkel TJ, Shi GP, Biessen EA: Leukocyte cathepsin S is a potent regulator of both cell and matrix turnover in advanced atherosclerosis. Arterioscler Thromb Vasc Biol 29: 188-194, 2009
32. Sukhova GK, Zhang Y, Pan JH, Wada Y, Yamamoto T, NaitoM, Kodama T, Tsimikas S, Witztum JL, Lu ML, Sakara Y, Chin MT, Libby P, Shi GP: Deficiency of cathepsin S reduces atherosclerosis in LDL receptordeficient mice. J Clin Invest 111: 897-906, 2003
33. Madhusudhan T, Wang H, Straub BK, Grone E, Zhou Q, Shahzad K, Muller-Krebs S, Schwenger V, Gerlitz B, Grinnell BW, Griffin JH, Reiser J, Grone HJ, Esmon CT, Nawroth PP, Isermann B: Cytoprotective signaling by activated protein C requires protease-activated receptor-3 in podocytes. Blood 119: 874-883, 2012
34. Alberelli MA, De Candia E: Functional role of protease activated receptors in vascular biology. Vascul Pharmacol 62: 72-81, 2014
35. Weil EJ, Lemley KV, Mason CC, Yee B, Jones LI, Blouch K, Lovato T, Richardson M, Myers BD, Nelson RG: Podocyte detachment and reduced glomerular capillary endothelial fenestration promote kidney disease in type 2 diabetic nephropathy. Kidney Int 82: 1010-1017, 2012
36. Prunotto M, Farina A, Lane L, Pernin A, Schifferli J, Hochstrasser DF, Lescuyer P, Moll S: Proteomic analysis of podocyte exosome-enriched fraction from normal human urine. J Proteomics 82: 193-229, 2013
37. Lindenmeyer MT, Eichinger F, Sen K, Anders HJ, Edenhofer I, Mattinzoli D, Kretzler M, Rastaldi MP, Cohen CD: Systematic analysis of a novel human renal glomerulus-enriched gene expression dataset. PLoS One 5: e11545, 2010
38. LechM,Avila-Ferrufino A, Skuginna V, SusantiHE, Anders HJ:Quantitative expression of RIG-like helicase, NOD-like receptor and inflammasomerelated mRNAs in humans and mice. Int Immunol 22: 717-728, 2010
39. Jadhav PK, Schiffler MA, Gavardinas K, Kim EJ, Matthews DP, Staszak MA, Coffey DS, Shaw BW, Cassidy KC, Brier RA, Zhang Y, Christie RM, Matter WF, Qing K, Durbin JD, Wang Y, Deng GG: Discovery of cathepsin S inhibitor LY3000328 for the treatment of abdominal aortic aneurysm. ACS Med Chem Lett 5: 1138-1142, 2014
40. Darisipudi MN, Kulkarni OP, Sayyed SG, Ryu M, Migliorini A, Sagrinati C, Parente E, Vater A, Eulberg D, Klussmann S, Romagnani P, Anders HJ: Dual blockade of the homeostatic chemokine CXCL12 and the proinflammatory chemokine CCL2 has additive protective effects on diabetic kidney disease. Am J Pathol 179: 116-124, 2011
41. Reichel CA, Khandoga A,AndersHJ, SchlondorffD, LuckowB, Krombach F: Chemokine receptors Ccr1, Ccr2, and Ccr5 mediate neutrophil migration to postischemic tissue. J Leukoc Biol 79: 114-122, 2006
42. Ninichuk V, Clauss S, Kulkarni O, Schmid H, Segerer S, Radomska E, Eulberg D, Buchner K, Selve N, Klussmann S, Anders HJ: Late onset of Ccl2 blockade with the Spiegelmer mNOX-E36-39PEG prevents glomerulosclerosis and improves glomerular filtration rate in db/db mice. Am J Pathol 172: 628-637, 2008
43. Mulay SR, Kulkarni OP, Rupanagudi KV, Migliorini A, Darisipudi MN, Vilaysane A, Muruve D, Shi Y, Munro F, Liapis H, Anders HJ: Calcium oxalate crystals induce renal inflammation by NLRP3-mediated IL-1beta secretion. J Clin Invest 123: 236-246, 2013
44. Teixeira Vde P, Blattner SM, Li M, Anders HJ, Cohen CD, Edenhofer I, Calvaresi N, Merkle M, Rastaldi MP, Kretzler M: Functional consequences of integrin-linked kinase activation in podocyte damage. Kidney Int 67: 514-523, 2005
45. Lech M, Avila-Ferrufino A, Allam R, Segerer S, Khandoga A, Krombach F, Garlanda C, Mantovani A, Anders HJ: Resident dendritic cells prevent postischemic acute renal failure by help of single Ig IL-1 receptorrelated protein. J Immunol 183: 4109-4118, 2009
46. Allam R, Kumar SV, Darisipudi MN, Anders HJ: Extracellular histones in tissue injury and inflammation. J Mol Med 92: 465-472, 2014
47. Shankland SJ, Pippin JW, Reiser J, Mundel P: Podocytes in culture: Past, present, and future. Kidney Int 72: 26-36, 2007
48. Lech M, Garlanda C, Mantovani A, Kirschning CJ, Schlondorff D, AndersHJ:Different roles of TiR8/Sigirr on toll-like receptor signaling in intrarenal antigen-presenting cells and tubular epithelial cells. Kidney Int 72: 182-192, 2007
49. Migliorini A, Angelotti ML, Mulay SR, Kulkarni OO, Demleitner J, Dietrich A, Sagrinati C, Ballerini L, Peired A, Shankland SJ, Liapis H, Romagnani P, Anders HJ: The antiviral cytokines IFN-alpha and IFNbeta modulate parietal epithelial cells and promote podocyte loss: Implications for IFN toxicity, viral glomerulonephritis, and glomerular regeneration. Am J Pathol 183: 431-440, 2013
50. Hagele H, Allam R, Pawar RD, Reichel CA, Krombach F, Anders HJ: Double-stranded DNA activates glomerular endothelial cells and enhances albumin permeability via a toll-like receptor-independent cytosolic DNA recognition pathway. Am J Pathol 175: 1896-1904, 2009
51. Subramanian A, Tamayo P,Mootha VK,Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES, Mesirov JP: Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A 102: 15545-15550, 2005